NCT02653300已完成2 期
An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)
Oramed, Ltd.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年9月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change in MRI-Proton Density Fat Fraction (MRI-PDFF)
研究概览
简要总结
This is an open, pilot study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM or pre-diabetes. The study will consist of a Screening, placebo run-in, treatment phase and end-of-study phase.
详细描述
This exploratory study will first enroll 10 patients with NASH and type 2 DM, to evaluate the safety of oral insulin and to measure the change in liver fat content.
At the completion of their 4-week follow-up period, results will be presented to the Helsinki Committee. Following approval, an additional 20 patients will be enrolled. The size of the study population was determined by the investigator (with literature review) to be sufficient to show trends of reducing liver fat content by analysis of MRI PDFF (MRI-Proton Density Fat Fraction) images, the FibroMax™ Test and Fibroscan® including Controlled Attenuation Parameter (CAP™). CAP™ is a measure of the ultrasound attenuation to quantify steatosis in the liver.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Known type 2 DM according to American Diabetic Association (one of the three needed): Fasting Plasma Glucose ≥126 mg/dl or 2h postprandial (PG) following 75g OGTT ≥ 200 mg/dl or HbA1C > 5.7% or on treatment with metformin
- •Abdominal ultrasound (US) proven fatty liver performed within 6 months before randomization, confirmed by central US.
- •Fat concentration in the liver of S2 (moderate steatosis, 6-32% hepatocytes with steatosis) or more as measured by Fibromax.
- •Signature of the written informed consent.
- •Negative pregnancy test at study entry for females of child bearing potential.
- •Females must have a negative urine pregnancy test result at screening, prior to the start of the run-in period, and at initiation of active dosing. A negative urine and serum pregnancy test must be obtained prior to active dosing. Males and females of childbearing potential must use two methods of contraception.
- •Females of non-childbearing potential are defined as postmenopausal who a) had more than 24 months since last menstrual cycle with menopausal levels of FSH, b) who are surgically menopausal.
- •For hypertensive patients, hypertension must be controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening with BP < 150/<95 mmHg
- •Patients previously treated with vitamin E (>400IU/day).
- •Glycaemia must be controlled (Glycosylated Hemoglobin A1C ≤9%) while any HbA1C increment should not exceed 1% during 6 months prior to enrolment).
排除标准
- •Patients with active (acute or chronic) liver disease other than NASH (e.g. viral hepatitis, genetic hemochromatosis, Wilson disease, alpha 1antitripsin deficiency, alcohol liver disease, drug induced liver disease) at the time of randomization.
- •ALT or AST ≥ 2 times ULN
- •Abnormal synthetic liver function (serum albumin ≤3.5gm%, INR >1.3).
- •Known alcohol and/or any other drug abuse or dependence in the last five years.
- •Weight >120 Kg
- •Known history or presence of clinically significant cardiovascular, gastrointestinal, metabolic (other than diabetes mellitus), neurologic, pulmonary, endocrine, psychiatric, neoplastic disorder or nephrotic syndrome.
- •History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including bile salt metabolites (e.g. inflammatory bowel disease (IBD), previous intestinal (ileal or colonic) operation, chronic pancreatitis, celiac disease or previous vagotomy.
- •Weight loss of more than 5% within 6 months prior to randomization.
- •History of bariatric surgery.
- •Uncontrolled blood pressure BP ≥150/
- •Non type 2 DM (type I, endocrinopathy, genetic syndromes etc).
- •Patients with HIV.
- •Daily alcohol intake >20 g/day for women and >30 g/day for men.
- •Treatment anti-diabetic medications other than metformin, such as DPP-4 inhibitors, GLP-1 receptor agonists, TZDs, etc.
- •Metformin, Fibrates, Statins, not provided on a stable dose in the last 6 months.
- •Patients who are treated with Valproic acid, Tamoxifen, Methotrexate, Amiodaron.
- •Chronic treatment with antibiotics (e.g. Rifaximin).
- •Homeopathic and/or Alternative treatments.
- •Uncontrolled hypothyroidism defined as Thyroid Stimulating Hormone >2X the upper limit of normal (UNLN).
- •Patients with renal dysfunction: eGFR< 40 ml/min.
- •Unexplained serum creatinine phosphokinase
结局指标
主要结局
Change in MRI-Proton Density Fat Fraction (MRI-PDFF)
时间窗: Two timepoints: Baseline (week 0) and Week 12
Absolute Change in MRI-Proton Density Fat Fraction (expressed as percent fat in the liver) from baseline to week 12
次要结局
- Mean Transient Elastography Measurement (Fibroscan)(Two timepoints: Baseline (week 0) and Week 12)
- Mean Fibrosis Score CAP™ (FibroMax)(Two timepoints: Baseline (week 0) and Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like SyndromeCRS - Cytokine Release SyndromeHLHNCT05306080University of Pennsylvania10
已完成
1 期
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon ResectionRecurrent Clostridioides Difficile InfectionColonic SurgeryNCT06692179University of Minnesota21
已完成
不适用
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened InhibitorsBasal Cell CarcinomaNCT01529450Anne Chang11
已完成
2 期
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing CholangitisPrimary Sclerosing Cholangitis (PSC)NCT02061540Mirum Pharmaceuticals, Inc.27
已完成
2 期
Treatment of white patches with Unani formulationsCTRI/2018/04/013349Central Council for Research in Unani Medicine61